The following articles (labelled with PubMed ID or TBD) are for your review
PMID | Data | Article Title | Organization |
26653735 |
81 |
Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treatment of Osteoarthritis. |
Pfizer |
26753813 |
22 |
Design and synthesis of an activity-based protein profiling probe derived from cinnamic hydroxamic acid. |
University of Minnesota |
25264600 |
64 |
Discovery of novel, highly potent, and selective quinazoline-2-carboxamide-based matrix metalloproteinase (MMP)-13 inhibitors without a zinc binding group using a structure-based design approach. |
Takeda Pharmaceutical |
25265401 |
38 |
Targeting matrix metalloproteinases: exploring the dynamics of the s1' pocket in the design of selective, small molecule inhibitors. |
Universidad Ceu San Pablo |
25192810 |
66 |
Thieno[2,3-d]pyrimidine-2-carboxamides bearing a carboxybenzene group at 5-position: highly potent, selective, and orally available MMP-13 inhibitors interacting with the S1¿ binding site. |
Takeda Pharmaceutical |
24044937 |
59 |
Aggrecanase-2 inhibitors based on the acylthiosemicarbazide zinc-binding group. |
University of Lille |
24900710 |
25 |
Discovery of a New Class of Potent MMP Inhibitors by Structure-Based Optimization of the Arylsulfonamide Scaffold. |
University of Florence |
23631440 |
44 |
Matrix metalloproteinase inhibitors based on the 3-mercaptopyrrolidine core. |
Florida State University |
23437776 |
37 |
Optimization of peptide hydroxamate inhibitors of insulin-degrading enzyme reveals marked substrate-selectivity. |
Mayo Clinic |
17275314 |
701 |
Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs. |
Pomona College |
21780776 |
40 |
Remarkable potential of thea-aminophosphonate/phosphinate structural motif in medicinal chemistry. |
Wroclaw University of Technology |
22737278 |
44 |
Structure-Activity Relationship for Thiirane-Based Gelatinase Inhibitors. |
TBA |
22175799 |
22 |
Discovery and evaluation of a non-Zn chelating, selective matrix metalloproteinase 13 (MMP-13) inhibitor for potential intra-articular treatment of osteoarthritis. |
Alantos Pharmaceuticals |
19715320 |
87 |
Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation. |
University of Florida |
18053726 |
364 |
Inhibitors of proteases and amide hydrolases that employ an alpha-ketoheterocycle as a key enabling functionality. |
Johnson & Johnson Pharmaceutical Research & Development |
18251495 |
69 |
Quinazolinones and pyrido[3,4-d]pyrimidin-4-ones as orally active and specific matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis. |
Pfizer |
18061445 |
103 |
Alpha,beta-cyclic-beta-benzamido hydroxamic acids: novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF-alpha converting enzyme (TACE). |
Bristol-Myers Squibb Research and Development |
17127067 |
21 |
Methotrexate gamma-hydroxamate derivatives as potential dual target antitumor drugs. |
Instituto Superior T£Cnico |
15713379 |
40 |
N-i-Propoxy-N-biphenylsulfonylaminobutylhydroxamic acids as potent and selective inhibitors of MMP-2 and MT1-MMP. |
Universit£ |
12773042 |
195 |
Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis. |
Wyeth Research |
11472217 |
157 |
Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo. |
Dupont Pharmaceuticals |
11472202 |
143 |
Potent and selective carboxylic acid-based inhibitors of matrix metalloproteinases. |
TBA |
10669559 |
180 |
Protease inhibitors: current status and future prospects. |
University of Queensland |
10649971 |
180 |
Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors. |
Parke-Davis Pharmaceutical Research |
10882358 |
62 |
Hydroxamic acid derivatives as potent peptide deformylase inhibitors and antibacterial agents. |
F. Hoffmann-La Roche |
10579818 |
162 |
Design, synthesis, and biological evaluation of potent thiazine- and thiazepine-based matrix metalloproteinase inhibitors. |
Procter and Gamble Pharmaceuticals |
9888835 |
42 |
Design and synthesis of phosphinamide-based hydroxamic acids as inhibitors of matrix metalloproteinases. |
Procter and Gamble Pharmaceuticals |
9733482 |
31 |
Discovery of potent, achiral matrix metalloproteinase inhibitors. |
Procter and Gamble Pharmaceuticals |
11327577 |
86 |
Heterocycle-based MMP inhibitors with P2' substituents. |
Procter and Gamble Pharmaceuticals |
22175825 |
19 |
Potent inhibitors of LpxC for the treatment of Gram-negative infections. |
Pfizer |
22017539 |
75 |
Fragment-based discovery of indole inhibitors of matrix metalloproteinase-13. |
Boehringer Ingelheim Pharmaceuticals |
22017477 |
35 |
Novel 1-hydroxypiperazine-2,6-diones as new leads in the inhibition of metalloproteinases. |
Instituto Superior T£Cnico |
22153340 |
37 |
Discovery of potent and selective matrix metalloprotease 12 inhibitors for the potential treatment of chronic obstructive pulmonary disease (COPD). |
Pfizer |
21866961 |
28 |
Selective water-soluble gelatinase inhibitor prodrugs. |
University of Notre Dame |
20726512 |
282 |
Orally active MMP-1 sparinga-tetrahydropyranyl anda-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease. |
Pfizer |
20638281 |
56 |
Structure and activity relationships of tartrate-based TACE inhibitors. |
Merck Research Laboratories |
21507637 |
102 |
MMP-13 selectivea-sulfone hydroxamates: a survey of P1' heterocyclic amide isosteres. |
Pfizer |
21458257 |
87 |
2-(2-Aminothiazol-4-yl)pyrrolidine-based tartrate diamides as potent, selective and orally bioavailable TACE inhibitors. |
Merck Research Laboratories |
24900296 |
38 |
Sulfonate-Containing Thiiranes as Selective Gelatinase Inhibitors |
TBA |
20965620 |
50 |
Structure-based approach to nanomolar, water soluble matrix metalloproteinases inhibitors (MMPIs). |
Protera |
21106451 |
39 |
Novel TNF-a converting enzyme (TACE) inhibitors as potential treatment for inflammatory diseases. |
Merck Research Laboratories |
20529684 |
112 |
Orally bioavailable dual MMP-1/MMP-14 sparing, MMP-13 selective alpha-sulfone hydroxamates. |
Pfizer |
20172725 |
49 |
Discovery and SAR of hydantoin TACE inhibitors. |
Merck Research Laboratories |
20022498 |
71 |
The discovery of novel tartrate-based TNF-alpha converting enzyme (TACE) inhibitors. |
Schering-Plough Research Institute |
20005097 |
58 |
Discovery of (pyridin-4-yl)-2H-tetrazole as a novel scaffold to identify highly selective matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis. |
Pfizer |
19703773 |
63 |
The identification of beta-hydroxy carboxylic acids as selective MMP-12 inhibitors. |
Gsk Medicines Research Centre |
19524436 |
27 |
Regioselective synthesis of methylated epigallocatechin gallate via nitrobenzenesulfonyl (Ns) protecting group. |
University of Shizuoka and Global Coe Program |
19725580 |
93 |
Identification of an orally efficacious matrix metalloprotease 12 inhibitor for potential treatment of asthma. |
Wyeth Research |
18835710 |
69 |
Discovery of novel hydroxamates as highly potent tumor necrosis factor-alpha converting enzyme inhibitors. Part II: optimization of the S3' pocket. |
Schering-Plough Research Institute |
| 97 |
Inhibition of Matrix Metalloproteinases: An examination of the S1′ pocket |
TBA |
| 36 |
Design, synthesis, activity, and structure of a novel class of matrix metalloproteinase inhibitors containing a heterocyclic P2′-P3′ amide bond isostere |
TBA |
| 40 |
Novel indolactam-based inhibitors of matrix metalloproteinases |
TBA |
18790648 |
317 |
Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge. |
University of Athens |
18782669 |
90 |
Introduction of the 4-(4-bromophenyl)benzenesulfonyl group to hydrazide analogs of Ilomastat leads to potent gelatinase B (MMP-9) inhibitors with improved selectivity. |
Université |
18442906 |
40 |
Novel bis-(arylsulfonamide) hydroxamate-based selective MMP inhibitors. |
North Dakota State University |
17719700 |
39 |
Peptidyl 3-substituted 1-hydroxyureas as isosteric analogues of succinylhydroxamate MMP inhibitors. |
Università |
17623656 |
34 |
Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects. |
Pfizer |
17576061 |
132 |
Synthesis and structure-activity relationship of a novel, non-hydroxamate series of TNF-alpha converting enzyme inhibitors. |
Bristol-Myers Squibb Pharmaceutical Research Institute |
17368021 |
55 |
Hydantoins, triazolones, and imidazolones as selective non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE). |
Bristol-Myers Squibb Pharmaceutical Research Institute |
17276676 |
112 |
A new 4-(2-methylquinolin-4-ylmethyl)phenyl P1' group for the beta-amino hydroxamic acid derived TACE inhibitors. |
Bristol-Myers Squibb Pharmaceutical Research Institute |
17088065 |
106 |
alpha-Biphenylsulfonylamino 2-methylpropyl phosphonates: enantioselective synthesis and selective inhibition of MMPs. |
Università |
17027261 |
153 |
Discovery of low nanomolar non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE). |
Bristol-Myers Squibb Pharmaceutical Research Institute |
16516466 |
175 |
Synthesis and structure-activity relationship of a novel, achiral series of TNF-alpha converting enzyme inhibitors. |
Bristol-Myers Squibb Pharmaceutical Research Institute |
16473009 |
23 |
Synthesis and evaluation of succinoyl-caprolactam gamma-secretase inhibitors. |
Bristol-Myers Squibb Pharmaceutical Research Institute |
16392792 |
29 |
Matrix metalloproteinase target family landscape: a chemometrical approach to ligand selectivity based on protein binding site analysis. |
Aventis Pharma Deutschland |
16153831 |
87 |
Synthesis and SAR of highly selective MMP-13 inhibitors. |
Wyeth Research |
16005220 |
52 |
Identification of potent and selective MMP-13 inhibitors. |
Wyeth Research |
14711305 |
26 |
Evaluation of P1'-diversified phosphinic peptides leads to the development of highly selective inhibitors of MMP-11. |
University of Athens |
14684295 |
109 |
Tetrahydroisoquinoline based sulfonamide hydroxamates as potent matrix metalloproteinase inhibitors. |
Chinese Academy of Sciences |
12877590 |
28 |
A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers. |
Pfizer |
12798337 |
6 |
Synthesis of radiolabeled biphenylsulfonamide matrix metalloproteinase inhibitors as new potential PET cancer imaging agents. |
Indiana University School of Medicine |
12408705 |
73 |
Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structure-activity relationships. |
Bristol-Myers Squibb |
11754593 |
148 |
Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors. |
Abbott Laboratories |
11585440 |
76 |
Discovery of macrocyclic hydroxamic acids containing biphenylmethyl derivatives at P1', a series of selective TNF-alpha converting enzyme inhibitors with potent cellular activity in the inhibition of TNF-alpha release. |
Dupont Pharmaceuticals |
11551755 |
18 |
Asymmetric synthesis of BB-3497--a potent peptide deformylase inhibitor. |
British Biotech Pharmaceuticals |
11454461 |
111 |
The development of new carboxylic acid-based MMP inhibitors derived from a cyclohexylglycine scaffold. |
Procter and Gamble Pharmaceuticals |
11412980 |
48 |
Discovery and characterization of the potent, selective and orally bioavailable MMP inhibitor ABT-770. |
Abbott Laboratories |
11327602 |
58 |
Novel 5,5-disubstitutedpyrimidine-2,4,6-triones as selective MMP inhibitors. |
Roche Research Center |
11150165 |
228 |
Development of new hydroxamate matrix metalloproteinase inhibitors derived from functionalized 4-aminoprolines. |
Procter and Gamble Pharmaceuticals |
10669564 |
189 |
Design and synthesis of piperazine-based matrix metalloproteinase inhibitors. |
Procter and Gamble Pharmaceuticals |
10639284 |
119 |
Design, synthesis, and biological evaluation of matrix metalloproteinase inhibitors derived from a modified proline scaffold. |
University of Florida |
10411481 |
144 |
Phosphinic pseudo-tripeptides as potent inhibitors of matrix metalloproteinases: a structure-activity study. |
Cea |
9873712 |
109 |
Aryl ketones as novel replacements for the C-terminal amide bond of succinyl hydroxamate MMP inhibitors. |
Abbott Laboratories |
9873491 |
56 |
The design, synthesis, and structure-activity relationships of a series of macrocyclic MMP inhibitors. |
Abbott Laboratories |
9632351 |
36 |
Rational design and combinatorial evaluation of enzyme inhibitor scaffolds: identification of novel inhibitors of matrix metalloproteinases. |
Affymax Research Institute |
9484512 |
130 |
Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives. |
Shionogi |
21524149 |
13 |
Design, synthesis and pharmacological evaluation of conformationally restricted N-arylsulfonyl-3-aminoalkoxy indoles as a potential 5-HT6 receptor ligands. |
Suven Life Sciences |
8632342 |
110 |
Pharmacologic characterization of the human 5-hydroxytryptamine2B receptor: evidence for species differences. |
Eli Lilly |
7651361 |
32 |
Characterization of (+/-)(-)[3H]epibatidine binding to nicotinic cholinergic receptors in rat and human brain. |
Georgetown University |
7518496 |
9 |
Cloning and expression of a 5-hydroxytryptamine7 receptor positively coupled to adenylyl cyclase. |
Syntex Discovery Research |
7515823 |
54 |
Actions of phenylglycine analogs at subtypes of the metabotropic glutamate receptor family. |
Novo Nordisk |
7509389 |
8 |
Pharmacological profile of FK480, a novel cholecystokinin type-A receptor antagonist: comparison to loxiglumide. |
Fujisawa Pharmaceutical |